We are live on ! Find out more
OC

Oppenheimer & Co Portfolio holdings

AUM $8.21B
1-Year Est. Return 28.81%
This Fund
S&P 500
This Quarter Est. Return
+7.34%
1 Year Est. Return
+28.81%
3 Year Est. Return
+92.54%
5 Year Est. Return
+114.67%
10 Year Est. Return
+429.8%
AUM
$5.01B
AUM Growth
+$272M
Cap. Flow
+$7.3M
Cap. Flow %
0.15%
Top 10 Hldgs %
17%
Holding
1,535
New
196
Increased
578
Reduced
560
Closed
103

Top Buys

Rank Stock Value
1
SPHB icon
Invesco S&P 500 High Beta ETF
SPHB
+$18M
2
XPO icon
XPO
XPO
+$11.4M
3
ABNB icon
Airbnb
ABNB
+$8.58M
4
TSLA icon
Tesla
TSLA
+$8.16M
5
META icon
Meta Platforms (Facebook)
META
+$7.69M

Top Sells

Rank Stock Value
1
KO icon
Coca-Cola
KO
+$24.1M
2
KMX icon
CarMax
KMX
+$14.2M
3
CRWD icon
CrowdStrike
CRWD
+$13.2M
4
AGNT
AGNT Inc
AGNT
+$12.3M
5
ILMN icon
Illumina
ILMN
+$11.2M

Sector Composition

Rank Sector Weight
1 Technology 17.28%
2 Financials 10.9%
3 Healthcare 10.6%
4 Consumer Discretionary 10.22%
5 Industrials 9.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ENLC
1401
DELISTED
ENLINK MIDSTREAM, LLC
ENLC
$98K ﹤0.01%
22,895
CFMS
1402
DELISTED
Conformis, Inc. Common Stock
CFMS
$94K ﹤0.01%
+3,788
New +$102K
KODK icon
1403
Kodak
KODK
$822M
$87K ﹤0.01%
+11,082
New +$101K
GMDA
1404
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$87K ﹤0.01%
+10,800
New +$99.1K
MBIO icon
1405
Mustang Bio
MBIO
$4.32M
$85K ﹤0.01%
34
+1
+3% +$2.97K
IEAWW
1406
DELISTED
Infrastructure and Energy Alternatives, Inc. Warrant
IEAWW
$85K ﹤0.01%
25,000
NBSE
1407
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$79K ﹤0.01%
+538
New +$97.5K
JMM icon
1408
Nuveen Multi-Market Income Fund
JMM
$54.6M
$74K ﹤0.01%
10,250
FPL
1409
DELISTED
FIRST TRUST NEW OPPORTUNITIES MLP & ENERGY FUND
FPL
$72K ﹤0.01%
13,453
+112
+0.8% +$548
CMCM
1410
Cheetah Mobile
CMCM
$86.6M
$70K ﹤0.01%
6,204
SAN icon
1411
Banco Santander
SAN
$201B
$70K ﹤0.01%
20,540
-8,005
-28% -$27.1K
OCSL icon
1412
Oaktree Specialty Lending
OCSL
$1.02B
$68K ﹤0.01%
+3,692
New +$66.4K
WATT icon
1413
Energous
WATT
$77.6M
$65K ﹤0.01%
27
OPK icon
1414
Opko Health
OPK
$985M
$62K ﹤0.01%
14,500
+2,000
+16% +$9.55K
AEG icon
1415
Aegon
AEG
$14B
$54K ﹤0.01%
+12,268
New +$51.4K
EGIO
1416
DELISTED
Edgio, Inc. Common Stock
EGIO
$54K ﹤0.01%
376
-17
-4% -$2.66K
TXMD icon
1417
TherapeuticsMD
TXMD
$23.5M
$53K ﹤0.01%
785
-500
-39% -$39.1K
PVLA
1418
Palvella Therapeutics
PVLA
$1.99B
$49K ﹤0.01%
238
BTG icon
1419
B2Gold
BTG
$5B
$48K ﹤0.01%
11,200
+1,000
+10% +$4.88K
WTER
1420
DELISTED
The Alkaline Water Company Inc. Common Stock
WTER
$48K ﹤0.01%
2,947
AMPE
1421
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
$42K ﹤0.01%
84
NGD
1422
DELISTED
New Gold Inc
NGD
$41K ﹤0.01%
26,946
-2,000
-7% -$3.62K
ADIL
1423
Adial Pharmaceuticals
ADIL
$7.31M
$35K ﹤0.01%
+23
New +$34.8K
OTLK icon
1424
Outlook Therapeutics
OTLK
$183M
$29K ﹤0.01%
+655
New +$25.1K
SENS icon
1425
Senseonics Holdings Inc
SENS
$263M
$26K ﹤0.01%
500

Similar funds

Oppenheimer & Co's Q1 2021 Portfolio in Review

As of Q1 2021, Oppenheimer & Co held 1,535 positions worth $5.01B, up 5.7% from $4.74B the previous quarter. Its ten largest holdings account for 17% of the portfolio.

Oppenheimer & Co's Q1 2021 filing shows 196 new, 578 increased, 560 reduced and 103 closed positions. Its largest new stake was Airbnb: 46,295 shares worth $8.7M. The largest sale was Coca-Cola, an estimated $24.1M.

By sector, the portfolio is most concentrated in Technology at 17% of assets, down from 19% a quarter earlier, followed by Financials and Healthcare.

  • Oppenheimer & Co's largest Q1 2021 buy was Airbnb: 46,295 shares worth $8.7M.
  • Oppenheimer & Co added most to Invesco S&P 500 High Beta ETF in Q1 2021, an estimated $18M increase.
  • Oppenheimer & Co's biggest Q1 2021 reduction was Coca-Cola, cutting an estimated $24.1M.
  • Oppenheimer & Co fully exited Tiffany & Co. in Q1 2021, selling an estimated $6.78M.
  • Oppenheimer & Co's ten largest holdings make up 17% of its $5.01B portfolio in Q1 2021.
  • Oppenheimer & Co opened 196 new positions and closed 103 in Q1 2021.
  • Oppenheimer & Co's portfolio value rose 5.7% quarter-over-quarter to $5.01B.

Based on Oppenheimer & Co's 13F filing for Q1 2021, filed 10 May 2021.